New drug combo aims to stop cervical cancer recurrence in high-risk patients
NCT ID NCT06727617
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug serplulimab to standard chemoradiotherapy after surgery can help prevent cervical cancer from returning in patients with multiple risk factors. About 134 women aged 18-65 with PD-L1 positive cervical cancer will be randomly assigned to receive either the drug combo or standard treatment alone. The goal is to see if the new approach improves how long patients stay cancer-free.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding radiation boost the power of immunotherapy in advanced cervical cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Could a condensed radiation course after cervical cancer surgery be just as safe and effective?
- Timing matters: early platelet booster may prevent dangerous drops in cervical cancer treatment
- Could 3 radiation doses beat 4 for cervical cancer?
- Nurse navigators boost cervical cancer screening in study